---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-016589"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2023-10-23T23:59:59+00:00"
generated_at: "2026-06-09T16:56:18.935472+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Olema reports Phase 2 palazestrant results: median PFS 4.6 mo in all patients; 7.2 mo in 2nd/3rd-line subset

## Summary
- Palazestrant (OP-1250) median PFS of 4.6 months (CBR 40%) in 86 heavily pretreated metastatic ER+/HER2- breast cancer patients.
- In ESR1-mutant patients (48% of ctDNA-assessed), median PFS 5.6 months, CBR 52%; in 2nd/3rd-line subset PFS 7.3 mo, CBR 59%.
- Safety: well-tolerated at 120 mg; Grade 4 neutropenia in 6 patients (all prior CDK4/6i), managed with dose reduction/discontinuation.
- Company plans to initiate OPERA-01, a Phase 3 pivotal monotherapy trial in 2nd/3rd-line metastatic breast cancer.
- Results presented at ESMO 2023; Olema hosted investor call on Oct 23, 2023.

## SEC filing metadata
- accession: 0001558370-23-016589
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2023-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000155837023016589/0001558370-23-016589-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000155837023016589/olma-20231022x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-016589
- JSON: https://secwatch.observer/filing/0001558370-23-016589.json
- Plain text: https://secwatch.observer/filing/0001558370-23-016589.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.